-
-
NCT00044681
-
Primary Citation
-
Data Specification
Not Yet Available
You are not logged in.
Please login to continue selecting trials.
Trial Information
Generic NameRisperidoneProduct NameRISPERDAL®Therapeutic AreaNervous SystemProduct ClassPsycholepticsPharmacological SubgroupAntipsychoticsChemical SubgroupOther AntipsychoticsCondition StudiedDepressive Disorder, Major
Sponsor Protocol NumberRIS-INT-93Enrollment258Data PartnerJohnson & Johnson% Female63.9%Mean/Median Age (Years)63.9% White90.9%
Supporting Documentation
- Collected Datasets Available
- Data Definition Specification Available
- Protocol with Amendments Available
- Statistical Analysis Plan Available
- Clinical Study Report Available
Approved Data Requests Associated with this Trial
- 2025-0068 : Large language models to quantitate placebo effect in neuropsychiatric disorders
- 2022-4992 : Temporal trajectories of side-effects associated with antipsychotic treatment: An individual participant data meta-analysis
- 2021-4835 : Role of clinical, historical and demographic factors in the response to antidepressants versus placebo
- 2021-4754 : Harnessing clinical trial data to inform real-world clinical decision making in the treatment of schizophrenia
- 2019-3958 : Machine Learning for predicting treatment efficacy and clinical categorizations across mental health disorders.
- 2019-3938 : Machine learning prediction of remission in patients given augmented treatment in major depression